|
1) Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964; 107: 159-72
|
|
|
|
2) Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosternism. J Clin Endocrinol Metab. 2006; 91: 454-9
|
|
|
|
|
|
3) Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006; 48: 219-24
|
|
|
|
|
|
4) Mosso LM, Carvajal CA, Maiz A, et al. A possible association between primary aldosteronism and a lower β-cell function. J Hypertens. 2006; 25: 2125-30
|
|
|
|
|
|
5) Yoneda T, Usukura M, Takata H, et al. The effects of spironolactone on insulin sensitivity and glucose metabolism in patients with idiopathic hyperaldosteronism. ENDO 2007/89th Annual Meeting. 2006. p. 93 (abs)
|
|
|
|
|
|
6) Colussi G, Catena C, Lappenna R, et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care. 2007; 30: 2349-54
|
|
|
|
|
|
7) Campion J, Maestro B, Mata F, et al. Inhibition by aldosterone of insulin receptor mRNA levels and insulin binding in U-937 human promono-cytic cells. J Steroid Biochem Molec Biol. 1999; 70: 211-8
|
|
|
|
|
|
8) Holzman JL, Liu L, Duke BJ, et al. Trans-activation of the IGF-1R by aldosterone. Am J Physiol Renal Physiol. 2007; 292: F1219-28
|
|
|
|
|
|
9) Lastra G, Whaley-Connell A, Manrique C, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG (mRen2) 27 rat. Am J Physiol Endocrinol Metab. 2008; 295: E110-6
|
|
|
|
|
|
10) Takeda Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralo-corticoid receptor antagonist. Hypertens Res. 2004; 27: 781-9
|
|
|
|
|
11) Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Cur Hypertens Rep. 2003; 5: 106-9
|
|
|
|
|
|
12) Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome. Is increased aldosterone in metabolic syndrome patients an additional risk factor？ Hypertension. 2008; 51: 1252-8
|
|
|
|
|
|
13) Guo C, Ricchiuti V, Lian BQ, et al. Mineralo-corticoid receptor blockade reverses obesity-related changes in expression of a adiponection, peroxisome proliferators-activated receptor-γ, and proinflammatory adipokines. Circulation. 2008; 117: 2253-61
|
|
|
|
|
|
14) Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003; 100: 14211-6
|
|
|
|
|
|
15) Nagase M, Yoshida S, Shibata S, et al. Enhanced aldosterone signaking in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006; 17: 3438-46
|
|
|
|
|
|
16) Krug AW, Vleugels K, Schinner S, et al. Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int J Obes (Lond). 2007; 31: 1605-16
|
|
|
|
|